乳癌液态切片检测设备市场：按技术、应用、最终用户、检测类型、检体类型、适应症和分销管道划分－2025-2032年全球预测

预计到 2032 年，乳癌液态切片检测设备市场规模将达到 44.6 亿美元，复合年增长率为 20.19%。

关键市场统计数据
基准年 2024	10.2亿美元
预计年份：2025年	12.3亿美元
预测年份 2032	44.6亿美元
复合年增长率 (%)	20.19%

重点关注液态切片检测在乳癌治疗和创新路径中不断变化的作用

液态切片技术正从一种小众研究工具转变为精准肿瘤学的关键组成部分，为检测肿瘤来源的生物标记提供了微创的组织切片检查替代方案。随着临床团队寻求更快、更安全、更可重复的方法来监测肿瘤动态，液态切片设备为改善早期检测、指导治疗选择和追踪微量残存疾病提供了机会。本文首先概述了循环肿瘤DNA、循环性肿瘤细胞和细胞外囊泡（如外泌体）的科学基础，并解释了检测的敏感度、特异性和通量如何影响其临床应用。

从实验室研究到临床应用的转变需要检测平台、样本处理流程和资料解读框架的协调一致。监管路径和报销政策也会影响推广应用的进程，而供应商在检测验证、自动化和互通性的投入将决定其竞争地位。最终，相关人员必须权衡技术性能、工作流程相容性、成本效益和临床效用，才能真正实现液态切片活检设备在乳癌常规管理中的应用前景。

变革性转变正在重塑乳癌液态切片检测的技术、临床实践和商业化。

由于检测化学、设备灵敏度和生物资讯学的进步，液态切片检测设备领域正在迅速改变。用于检测低频变异的高解析度技术以及结合ctDNA、CTC和外泌体成分的多分析方法正在扩大其临床应用范围。同时，样本处理和标准化的改进降低了分析前变异性，从而实现了更可靠的纵向监测。这些技术进步与不断完善的临床指引相辅相成，后者日益认识到微创诊断在治疗选择和疾病监测方面的价值。

在商业方面，诊断开发人员、临床实验室和肿瘤中心之间的策略合作正在加速证据产生和真实世界检验。合作伙伴优先考虑可扩展的工作流程和云端分析，以支援分散式检查和远端监测。此外，支付方的讨论正转向基于价值的报销模式，优先考虑那些能够显着改善治疗效果或降低后续成本的诊断方法。总而言之，这些转变正在促进科学成熟度和商业性准备的融合，从而改变临床医生和医疗系统进行乳癌检测和管理的方式。

评估2025年美国关税变化对诊断设备製造商供应链、成本和策略采购的累积影响

美国近期关税调整正对整个医疗设备供应链产生连锁反应，迫使诊断设备製造商重新评估筹资策略和成本结构。数位PCR和定序设备的关键组件，例如微流体晶片、特殊聚合物和半导体光学元件，可能面临更高的到岸成本，迫使供应商评估近岸外包、双重采购或重新设计以替换组件等方案。对于垂直整合的试剂和耗材供应商而言，关税带来的价格压力可能会影响其利润率，并加速与代工製造商的谈判，以确保长期供应协议的达成。

为应对这些压力，一些机构正在加强供应商资格审核和库存管理，同时加快对本地製造能力的投资，以降低风险。监管机构和物流团队也在更紧密地合作，以确保试剂供应的连续性，并最大限度地减少对临床检测服务的干扰。因此，采购决策不再仅基于单位成本，而是同时考虑供应弹性、前置作业时间和库存承载能力，进而影响整个诊断生态系统的长期策略规划。

关键细分洞察，重点在于技术选择、应用、使用者环境、检体方法、样本工作流程、临床适应症和通路。

我们的細項分析揭示了技术创新和应用正在整合的领域，以及为何某些平台在特定应用场景中更受青睐。我们的技术细分比较了数位PCR、次世代定序和即时PCR ，评估了基于晶片和液滴的数位PCR形式、标靶定序、全外EXOME定序和全基因组定序等次世代定序，以及基于染料和基于探针的即时PCR。这些差异对于分析灵敏度、多重检测能力和单次检测成本至关重要，而这些因素反过来又会影响临床应用。

应用细分评估循环性肿瘤细胞、循环肿瘤DNA和外泌体，其中外泌体进一步细分为外泌体DNA和外泌体RNA。最终使用者细分主要针对合约研究组织、诊断实验室、医院/诊所和研究中心，每个机构对通量、週转时间和法规遵循都有不同的要求。检测类型细分区分体外诊断设备与试剂与实验室自建检测方法。体外诊断设备分为仪器和试剂两类，而实验室自建检测方法通常分为基于NGS的LDT和基于PCR的LDT，每种方法都有其自身的验证和商业化路径。

检体类型细分将血浆、血清和全血作为影响产量比率和检测性能的重要分析前变数进行分析。适应症细分区分了早期检测、预后、復发检测和治疗监测等不同的临床终点，这些终点驱动着检测方法的选择和证据的产生。最后，销售管道细分对比了直销、线上销售和第三方分销商，并认识到线上销售是透过电子商务平台和製造商网站进行的，这会影响通路策略、定价和客户支援。整合这些细分观点有助于供应商明确其研发、监管工作和商业性资源应集中在哪些方面，从而使产品特性与最终用户需求和临床价值相符。

关键区域洞察解释了主要全球区域的采纳动态、医疗保健系统优先事项和法律规范如何差异，以及这些差异如何影响部署策略。

区域动态将影响液态切片检测设备的采用、报销以及在肿瘤诊疗路径中的整合方式。在美洲，临床网路和学术中心通常推动早期临床检验和应用，并得到分散式检查基础设施和蓬勃发展的私人检测产业的支持。同时，在欧洲、中东和非洲，统一的监管环境和公共报销框架影响液体活检设备的采用，集中式参考实验室与支付方合作，以证明其健康经济价值。在亚太地区，基因组学基础设施的快速投资、不断扩大的临床试验活动以及多样化的公共和私人医疗模式，为集中式和即时检测解决方案创造了机会。

这些区域差异会影响产品设计，从仪器尺寸和试剂低温运输要求到语言本地化以及与电子健康记录的集成，无一例外。因此，打入市场策略也必须因地制宜。一些地区优先考虑广泛的临床效用数据和卫生技术评估，而其他地区则更注重成本效益和可扩展部署。与区域实验室网路、关键意见领袖和当地监管伙伴关係建立策略合作伙伴关係，对于推动临床应用以及与不同地区的支付方成功谈判至关重要。

对竞争对手进行竞争考察，整合竞争提案、差异化策略和联盟模式，进而塑造诊断药物研发公司的竞争格局。

领先的诊断公司和新兴的专业公司正在采取互补策略来实现产品差异化。一些公司专注于平台层面的整合，将高灵敏度仪器与专有试剂和云端基础分析结合，建构能够吸引实验室客户的稳固生态系统。另一些公司则专注于特定的临床适应症和检体类型，优化检测化学方法，用于早期检测和微小残留病灶监测，在这些领域，超高的灵敏度和特异性至关重要。受託研究机构和临床服务实验室也发挥关键作用，它们在监管部门核准之前，为新型检测方法提供验证流程和规模化生产能力。

技术提供者、学术中心和肿瘤网络之间的伙伴关係已成为产生临床证据并加速将其纳入指南的主要途径。策略性併购和授权协议不断重塑能力结构，使一些供应商能够填补生物资讯学、样本处理和全球分销方面的空白。在选择合作伙伴和供应商时，决策者必须权衡技术优势、证据产生能力和商业覆盖范围，以实现可持续的临床和商业性成果。

为寻求扩大临床应用、优化产品市场契合度并维持液态切片检测领域竞争优势的行业领导者提供切实可行的建议

为了将科学进步转化为商业性成功，产业领导者应优先考虑与特定临床应用案例相符的策略性证据产生。设计能够证明产品在早期检测、復发检测或治疗监测方面具有更高临床价值的试验，并儘早与关键意见领袖合作，共同製定临床路径。同时，应投资稳健的分析前工作流程以及与实验室资讯系统的互通性，以最大限度地减少医院实验室和参考中心采用该产品的障碍。製造商还应评估混合商业化策略，将面向高触感客户的直接销售与线上通路和分销商关係相结合，以扩大市场覆盖范围。

在营运方面，透过多元化采购、在地化生产或签订长期供应商协议来增强供应链韧性，可以降低关税和物流风险。在产品方面，应优先考虑模组化和软体升级，使仪器能够随着生物资讯学的发展而演进，而无需更换硬体。最后，应制定与支付方合作的策略，将诊断定位为价值驱动因素，并合作进行结果研究和真实世界证据研究，以支持报销谈判和长期应用。

本报告的调查方法阐述了支撑研究结果和见解的跨学科方法、资料三角验证和检验步骤。

调查方法整合了专家文献综述、监管和政策分析以及结构化的相关人员参与，以确保观点平衡且切实可行。主要资讯来源包括对临床专家、实验室主任、采购人员和行业高管的访谈，以了解实践现状、应用障碍和商业化策略。二级资讯来源包括同行评审出版物、会议论文集以及公开的监管文件和指导文件，以提供检测性能和临床效用的技术说明。

分析人员采用严谨的三角验证流程，交叉检验研究结果，并将访谈内容与已发表的证据和产品规格进行比对。在条件允许的情况下，透过记录研究纳入标准、相关人员访谈范围以及临床终点解读的理由，确保调查方法的透明度。这种方法确保了结论既反映了最新的科学认知，也考虑了影响液态切片设备应用和规模化推广的现实限制。

总结全文，涵盖机会领域、持续存在的挑战以及下一阶段临床和商业性开发策略重点。

液态切片设备处于技术、临床需求和医疗保健系统优先事项的关键交汇点。非侵入性检测肿瘤衍生讯号能力的提升，为改善早期检测、优化预后和加强治疗监测提供了实际的机会。然而，要实现这些机会，需要解决技术差异性问题，使证据产生与支付方的期望相符，并确保工作流程与临床实验室操作无缝衔接。持续存在的挑战包括：协调分析前操作流程、证明疗效的显着改善，以及建立能够反映诊断价值的永续报销机制。

展望未来，那些能够将严谨的临床验证、实用的产品设计以及战略伙伴关係关係相结合的相关人员，将最有利于把检测方法转化为广泛应用的临床工具。注重模组化平台、建立稳健的供应链以及与监管机构和支付方生态系统的合作，将加速检测方法的应用。总而言之，下一阶段需要研发人员、临床医生、实验室和医疗保健系统共同努力，将前景看好的技术转化为乳癌诊疗的常规组成部分。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 将人工智慧演算法整合到ctDNA分析中，以提高早期检测的灵敏度
• 开发一种基于甲基化的超灵敏检测方法，用于监测乳癌患者的微量残存疾病
• 新兴的微流体晶片平台能够快速、高通量地分离循环性肿瘤细胞，用于常规诊断。
• 临床上将ctDNA和外泌体RNA合併分析应用于转移性乳癌的个人化治疗决策
• 监管核准和报销途径将加速下一代液态切片技术的市场准入
• 诊断公司与製药公司在标靶治疗伴随诊断的合作
• 标准化工作主要集中在分析前工作流程上，以减少不同实验室间液态切片样本处理的差异。
• 开发一种用于门诊和家庭环境中分散式乳癌监测的即时液态切片设备
• 整合多体学工作流程，结合蛋白质体学和基因生物标誌物，以提高早期乳癌筛检的特异性
• 将液态切片结果与人工智慧主导的数位病理学相结合，以实现全面的肿瘤分析和预后评估。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章乳癌液态切片检测设备市场（依技术划分）

• 数位PCR
  • 基于晶片的数位PCR
  • 液滴式数位PCR
• 下一代定序
  • 标靶定序
  • 全EXOME定序
  • 全基因组定序
• 即时PCR
  • 基于染料的PCR
  • 基于探针的PCR

第九章乳癌液态切片检测设备市场（按应用领域划分）

• 循环性肿瘤细胞
• 循环肿瘤DNA
• 外泌体
  • 外泌体DNA
  • 外泌体RNA

第十章乳癌液态切片检测设备市场（以最终用户划分）

• 受託研究机构
• 诊断实验室
• 医院和诊所
• 研究中心

第十一章乳癌液态切片检测设备市场（依检测类型划分）

• 体外诊断
  • 装置
  • 试剂
• 实验室自建测试
  • 基于NGS的LDT
  • 基于PCR的LDT

第十二章乳癌液态切片检测设备市场（依样本类型划分）

• 电浆
• 血清
• 全血

第十三章乳癌液态切片检测设备市场（依适应症划分）

• 早期检测
• 预后
• 復发检测
• 治疗监测

第十四章乳癌液态切片检测设备市场（依通路划分）

• 直销
• 线上销售
  • 电子商务平台
  • 製造商网站
• 第三方经销商

第十五章乳癌液态切片检测设备市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十六章乳癌液态切片检测设备市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十七章 各国乳癌液态切片检测设备市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十八章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • F. Hoffmann-La Roche AG
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Natera, Inc.
  • Qiagen NV
  • Bio-Rad Laboratories, Inc.
  • Sysmex Corporation
  • Grail, Inc.
  • Epigenomics AG

The Breast Cancer Liquid Biopsy Testing Devices Market is projected to grow by USD 4.46 billion at a CAGR of 20.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.02 billion
Estimated Year [2025]	USD 1.23 billion
Forecast Year [2032]	USD 4.46 billion
CAGR (%)	20.19%

A focused introduction to the evolving role of liquid biopsy testing in breast cancer care and innovation pathways

Liquid biopsy technologies have moved from niche research tools to pivotal components of precision oncology, offering minimally invasive alternatives to tissue biopsies for detecting tumor-derived biomarkers. As clinical teams seek faster, safer, and more repeatable modalities to monitor tumor dynamics, liquid biopsy testing devices present opportunities to improve early detection, guide therapeutic selection, and track minimal residual disease. This introduction sets the stage by clarifying the scientific underpinnings-circulating tumor DNA, circulating tumor cells, and extracellular vesicles such as exosomes-and by describing how assay sensitivity, specificity, and throughput shape clinical applicability.

Transitioning from bench to bedside requires alignment across assay platforms, sample handling protocols, and data interpretation frameworks. Regulatory pathways and reimbursement considerations further influence adoption timelines, while vendor investments in assay validation, automation, and interoperability determine competitive positioning. Ultimately, stakeholders must balance technical performance with workflow compatibility, cost-efficiency, and clinical utility to realize the promise of liquid biopsy testing devices in routine breast cancer management.

Transformative shifts reshaping technology, clinical practice, and commercialization in breast cancer liquid biopsy testing

The landscape of liquid biopsy testing devices has undergone rapid transformation driven by advances in assay chemistry, instrument sensitivity, and bioinformatics. High-resolution techniques that detect low-frequency variants and multi-analyte approaches combining ctDNA, CTCs, and exosomal content are expanding clinical use cases. Concurrently, improvements in sample processing and standardization have reduced pre-analytical variability, enabling more reliable longitudinal monitoring. These technical gains are complemented by evolving clinical guidelines that increasingly recognize the value of minimally invasive diagnostics for treatment selection and disease surveillance.

On the commercialization front, strategic collaborations between diagnostic developers, clinical laboratories, and oncology centers are accelerating evidence generation and real-world validation. Partners are prioritizing scalable workflows and cloud-enabled analytics to support decentralized testing and remote monitoring. Moreover, payer dialogue has shifted toward value-based reimbursement for diagnostics that demonstrably improve outcomes or reduce downstream costs. Taken together, these shifts create a convergence of scientific maturity and commercial readiness that is changing how clinicians and health systems approach breast cancer detection and management.

Assessing the cumulative impact of United States tariff changes in 2025 on supply chains, costs, and strategic sourcing for diagnostic device manufacturers

Recent tariff adjustments in the United States have reverberated across medical device supply chains, prompting diagnostic manufacturers to reassess sourcing strategies and cost structures. Components such as microfluidic chips, specialty polymers, and semiconductor-based optics that are integral to digital PCR and sequencing instruments may face higher landed costs, compelling vendors to evaluate nearshoring, dual sourcing, or redesign for component substitution. For vertically integrated suppliers of reagents and consumables, tariff-induced price pressure can affect margin profiles and may accelerate negotiations with contract manufacturers to secure long-term supply agreements.

In response to these pressures, some organizations are intensifying supplier qualification and inventory management practices while accelerating investments in local manufacturing capabilities to mitigate exposure. Regulatory and logistics teams are also collaborating more closely to ensure continuity of reagent supply and to minimize disruptions to clinical testing services. As a result, procurement decisions increasingly weigh not only unit cost but also supply resilience, lead times, and inventory carrying implications, shaping longer-term strategic planning across the diagnostic ecosystem.

Key segmentation insights that illuminate technological choices, applications, user environments, testing approaches, specimen workflows, clinical indications, and distribution pathways

Segmentation analysis clarifies where innovation and adoption are concentrated and why certain platforms gain traction in specific use cases. Technology segmentation compares digital PCR, next generation sequencing, and real time PCR, with digital PCR further differentiated into chip based and droplet digital formats, next generation sequencing spanning targeted sequencing, whole exome sequencing, and whole genome sequencing, and real time PCR evaluated across dye based and probe based chemistries. These distinctions matter for analytical sensitivity, multiplexing capacity, and cost per assay, which in turn influence clinical uptake.

Application segmentation assesses circulating tumor cells, circulating tumor DNA, and exosomes, with exosomes further disaggregated into exosomal DNA and exosomal RNA; each analyte class offers distinct biological insight and requires tailored extraction and analysis workflows. End user segmentation highlights contract research organizations, diagnostic laboratories, hospitals and clinics, and research centers as primary adopters, with differing demands for throughput, turnaround time, and regulatory compliance. Test type segmentation contrasts in vitro diagnostic instruments and reagents against laboratory developed tests, noting that in vitro diagnostics split into instrument and reagent categories while laboratory developed tests are often grouped as NGS based LDTs and PCR based LDTs, each with unique validation and commercialization pathways.

Sample type segmentation examines plasma, serum, and whole blood as critical pre-analytical variables that affect yield and assay performance. Indication segmentation differentiates early detection, prognosis, recurrence detection, and treatment monitoring as distinct clinical endpoints that drive assay selection and evidence generation. Finally, distribution channel segmentation contrasts direct sales, online sales, and third party distributors, recognizing that online sales may occur via e-commerce platforms or manufacturer websites, which impacts channel strategy, pricing, and customer support. Integrating these segmentation perspectives reveals where vendors should concentrate R&D, regulatory efforts, and commercial resources to align product features with end-user needs and clinical value.

Key regional insights that explain how adoption dynamics, health system priorities, and regulatory frameworks vary across major global regions and influence deployment strategies

Regional dynamics shape how liquid biopsy testing devices are adopted, reimbursed, and integrated with oncology pathways. In the Americas, clinical networks and academic centers often drive early clinical validation and adoption, supported by infrastructure for decentralized testing and an active private laboratory sector. Meanwhile, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts and public reimbursement frameworks influence uptake, and where centralized reference laboratories collaborate with healthcare payers to demonstrate health economic value. In Asia-Pacific, rapid investments in genomics infrastructure, expanding clinical trial activity, and diverse public-private healthcare models create opportunities for both centralized and point-of-care solutions.

These regional differences affect product design, from instrument footprint and reagent cold-chain requirements to language localization and integration with electronic health records. Market entry strategies must therefore be tailored: some regions prioritize extensive clinical utility data and health technology assessments, whereas others emphasize cost-efficiency and scalable deployment. Strategic partnerships with regional laboratory networks, key opinion leaders, and local regulatory experts are essential to accelerate clinical adoption and to navigate payer negotiations across these varied geographies.

Key company insights that synthesize competitive offers, differentiation strategies, and collaboration patterns shaping the competitive landscape for diagnostic developers

Leading diagnostic companies and emerging specialists are pursuing complementary approaches to differentiate their offerings. Some firms emphasize platform-level integration-pairing high-sensitivity instruments with proprietary reagents and cloud-based analytics-to create defensible ecosystems that lock in laboratory customers. Other organizations focus on niche clinical indications or specimen types, optimizing assay chemistry for early detection or minimal residual disease monitoring where ultra-high sensitivity and specificity are prerequisites. Contract research organizations and clinical service laboratories also play a critical role, providing validation pipelines and scaling capabilities for novel assays prior to regulatory clearance.

Partnerships between technology providers, academic centers, and oncology networks have become a primary vehicle for generating clinical evidence and accelerating guideline inclusion. Strategic M&A activity and licensing agreements continue to reconfigure capability stacks, enabling some vendors to bridge gaps in bioinformatics, sample processing, or global distribution. For decision-makers, choosing partners and suppliers involves balancing technical merit, evidence generation capacity, and commercialization reach to achieve durable clinical and commercial outcomes.

Actionable recommendations for industry leaders aiming to scale clinical adoption, optimize product-market fit, and sustain competitive advantage in liquid biopsy testing

To translate scientific advances into commercial success, industry leaders should prioritize strategic evidence generation that aligns with specific clinical use cases. Design studies that demonstrate incremental clinical value in early detection, recurrence detection, or therapy monitoring, and engage key opinion leaders early to shape clinical pathways. In parallel, invest in robust pre-analytical workflows and interoperability with laboratory information systems to minimize barriers to adoption among hospital laboratories and reference centers. Manufacturers should also evaluate hybrid commercialization approaches that combine direct sales for high-touch accounts with online channels and distributor relationships to broaden reach.

Operationally, strengthening supply chain resilience through diversified sourcing, local manufacturing options, or longer-term supplier agreements will reduce exposure to tariff and logistics risks. From a product perspective, prioritize modularity and software-enabled upgrades so instruments can evolve with bioinformatic advances without requiring full hardware replacement. Finally, pursue payer engagement strategies that frame diagnostics as value drivers, collaborating on outcomes studies and real-world evidence generation to support reimbursement conversations and long-term adoption.

Research methodology that explains the multidisciplinary approach, data triangulation, and validation steps underpinning the report's findings and insights

The research methodology integrates technical literature review, regulatory and policy analysis, and structured stakeholder engagement to ensure a balanced and actionable perspective. Primary inputs include interviews with clinical experts, laboratory directors, procurement leads, and industry executives to capture operational realities, adoption barriers, and commercialization strategies. Secondary sources span peer-reviewed publications, conference proceedings, and publicly available regulatory filings and guidance documents to ground technical statements about assay performance and clinical utility.

Analysts conducted a rigorous triangulation process to cross-validate findings, reconciling interview insights with published evidence and product specifications. Where possible, methodological transparency was maintained by documenting inclusion criteria for studies, the scope of stakeholder interviews, and the rationale for interpreting clinical endpoints. This approach ensures that conclusions reflect both the latest scientific understanding and real-world constraints that influence implementation and scale-up of liquid biopsy testing devices.

Concluding synthesis that encapsulates opportunity areas, persistent challenges, and strategic priorities for the next phase of clinical and commercial development

Liquid biopsy testing devices occupy a pivotal intersection of technology, clinical need, and health system priorities. The growing capability to detect tumor-derived signals noninvasively presents tangible opportunities to improve early detection, refine prognosis, and enhance treatment monitoring. Nonetheless, realization of these opportunities hinges on addressing technical variability, aligning evidence generation with payer expectations, and ensuring that workflows integrate seamlessly with clinical laboratory operations. Persistent challenges include harmonizing pre-analytical practices, demonstrating clear outcome improvements, and creating sustainable reimbursement pathways that reflect the diagnostic's value contribution.

Looking ahead, stakeholders who combine rigorous clinical validation, pragmatic product design, and strategic partnerships will be best positioned to translate assays into widely adopted clinical tools. Emphasizing modular platforms, resilient supply chains, and engagement with regulatory and payer ecosystems will accelerate adoption. In sum, the next phase requires coordinated action across developers, clinicians, laboratories, and health systems to transform promising technologies into routine components of breast cancer care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of artificial intelligence algorithms for ctDNA analysis to improve early detection sensitivity
• 5.2. Development of ultrasensitive methylation-based assays for minimal residual disease monitoring in breast cancer patients
• 5.3. Emergence of microfluidic chip platforms enabling rapid high-throughput isolation of circulating tumor cells in routine diagnostics
• 5.4. Clinical adoption of combined ctDNA and exosomal RNA profiling for personalized treatment decision support in metastatic breast cancer
• 5.5. Regulatory approvals and reimbursement pathways accelerating market access for next-generation liquid biopsy tests
• 5.6. Partnerships between diagnostics firms and pharmaceutical companies for companion diagnostics in targeted therapies
• 5.7. Standardization initiatives focused on pre-analytical workflows to reduce variability in liquid biopsy sample processing across laboratories
• 5.8. Advancement of point-of-care liquid biopsy devices for decentralized breast cancer monitoring in outpatient and home settings
• 5.9. Integration of multi-omics workflows combining proteomic and genomic biomarkers to enhance specificity in early breast cancer screening
• 5.10. Expansion of AI-driven digital pathology integration with liquid biopsy results for comprehensive tumor profiling and prognostic assessment

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Liquid Biopsy Testing Devices Market, by Technology

• 8.1. Digital PCR
  • 8.1.1. Chip Based Digital PCR
  • 8.1.2. Droplet Digital PCR
• 8.2. Next Generation Sequencing
  • 8.2.1. Targeted Sequencing
  • 8.2.2. Whole Exome Sequencing
  • 8.2.3. Whole Genome Sequencing
• 8.3. Real Time PCR
  • 8.3.1. Dye Based PCR
  • 8.3.2. Probe Based PCR

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Application

• 9.1. Circulating Tumor Cells
• 9.2. Circulating Tumor DNA
• 9.3. Exosomes
  • 9.3.1. Exosomal DNA
  • 9.3.2. Exosomal RNA

10. Breast Cancer Liquid Biopsy Testing Devices Market, by End User

• 10.1. Contract Research Organizations
• 10.2. Diagnostic Laboratories
• 10.3. Hospitals And Clinics
• 10.4. Research Centers

11. Breast Cancer Liquid Biopsy Testing Devices Market, by Test Type

• 11.1. In Vitro Diagnostic
  • 11.1.1. Instruments
  • 11.1.2. Reagents
• 11.2. Laboratory Developed Test
  • 11.2.1. NGS Based LDT
  • 11.2.2. PCR Based LDT

12. Breast Cancer Liquid Biopsy Testing Devices Market, by Sample Type

• 12.1. Plasma
• 12.2. Serum
• 12.3. Whole Blood

13. Breast Cancer Liquid Biopsy Testing Devices Market, by Indication

• 13.1. Early Detection
• 13.2. Prognosis
• 13.3. Recurrence Detection
• 13.4. Treatment Monitoring

14. Breast Cancer Liquid Biopsy Testing Devices Market, by Distribution Channel

• 14.1. Direct Sales
• 14.2. Online Sales
  • 14.2.1. E Commerce Platforms
  • 14.2.2. Manufacturer Website
• 14.3. Third Party Distributors

15. Breast Cancer Liquid Biopsy Testing Devices Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Breast Cancer Liquid Biopsy Testing Devices Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Breast Cancer Liquid Biopsy Testing Devices Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. F. Hoffmann-La Roche AG
  • 18.3.2. Guardant Health, Inc.
  • 18.3.3. Illumina, Inc.
  • 18.3.4. Thermo Fisher Scientific Inc.
  • 18.3.5. Natera, Inc.
  • 18.3.6. Qiagen N.V.
  • 18.3.7. Bio-Rad Laboratories, Inc.
  • 18.3.8. Sysmex Corporation
  • 18.3.9. Grail, Inc.
  • 18.3.10. Epigenomics AG

LIST OF FIGURES

• FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL BREAST C